TY - JOUR
T1 - Atopic dermatitis
T2 - Phototherapy and systemic therapy
AU - Davis, Dawn Marie
AU - Borok, Jenna
AU - Udkoff, Jeremy
AU - Lio, Peter
AU - Spergel, Jonathan
N1 - Funding Information:
1Department of Dermatology and Pediatrics, Mayo Clinic Rochester, Minnesota. 2Division of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, San Diego, California. 3Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, La Jolla, California. 4Departments of Dermatology and Pediatrics, Northwestern University Fein-berg School of Medicine and Medical Dermatology Associates of Chicago, Chicago, Illinois. 5Division of Allergy and Immunology, The Children’s Hospital of Philadelphia Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania. Disclosures: Dr Davis and Ms Borok have nothing to disclose. Mr Udkoff reports personal fees from Lucid Group 3AD Bibliographic Fellowship outside the submitted work. Dr Lio reports personal fees from Regeneron/Sanofi, personal fees from Pfizer, outside the submitted work. Dr Spergel reports grants and personal fees from DBV Technologies, grants from AImmune Therapeutics, grants from NIH, grants from Food Allergy Research Education, personal fees from Rockpointe, and personal fees from Meeting Education International, outside the submitted work. Correspondence: Dawn Marie Davis, MD; Davis.DawnMarie@mayo.edu
Publisher Copyright:
© 2017 Frontline Medical Communications.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.
AB - The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.
UR - http://www.scopus.com/inward/record.url?scp=85046084221&partnerID=8YFLogxK
U2 - 10.12788/j.sder.2017.027
DO - 10.12788/j.sder.2017.027
M3 - Article
AN - SCOPUS:85046084221
SN - 1085-5629
VL - 36
SP - 118
EP - 123
JO - Seminars in Cutaneous Medicine and Surgery
JF - Seminars in Cutaneous Medicine and Surgery
IS - 3
ER -